Shanghai MicroPort CardioFlow Medtech develops minimally invasive therapies utilizing catheter-based techniques for the treatment of structural heart diseases. Their solutions aim to reduce patient recovery time and minimize surgical risks associated with traditional open-heart procedures.
Funding
$130M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional open-heart surgeries for structural heart diseases carry significant risks and require lengthy recovery periods for patients. Minimally invasive alternatives are needed to reduce patient trauma and improve outcomes.
Solution
MicroPort CardioFlow Medtech develops and commercializes minimally invasive transcatheter solutions for treating structural heart diseases. Their product portfolio focuses on catheter-based technologies designed to replace or repair diseased heart valves without the need for open-heart surgery. These therapies aim to reduce procedural complications, shorten hospital stays, and accelerate patient recovery. By leveraging advanced engineering and materials science, MicroPort CardioFlow Medtech strives to expand access to innovative cardiac care and improve the quality of life for patients with valvular heart conditions.
Target Audience
The primary target audience includes interventional cardiologists, cardiac surgeons, and hospitals specializing in the treatment of structural heart diseases.
Features
- Transcatheter aortic valve implantation (TAVI) systems for treating aortic stenosis
- Catheter-based delivery systems for precise valve placement and deployment
- Self-expanding valve frames designed for optimal hemodynamics and durability
- Minimally invasive access techniques to reduce surgical trauma
- Advanced imaging technologies for real-time procedural guidance